GET DAILY SIGNALSBiofrontera (BFRI) Stock: Is the $6.00 Target Pointing to +575% Upside?
Key Takeaways
- The central stock price target is $6.00, the arithmetic mean of two verified analyst targets: $3.00 from Benchmark and $9.00 from Roth MKM.
- At a latest price near $0.89, reaching $6.00 implies an upside of roughly 575%, a very large move even by small-cap biotech standards.
- The analyst range is unusually wide, from $3.00 to $9.00, reflecting sharp disagreement over how much the company's recent FDA approval is worth.
- The strongest supporting factor is the September 2026 FDA approval of Ameluz Red Light PDT for superficial basal cell carcinoma, a first-of-its-kind skin-cancer indication.
- The biggest risks include a micro-cap valuation, ongoing net losses, limited cash, and a Nasdaq bid-price compliance notice that raises the possibility of a reverse stock split.
- For more context, review the ticker's Major News, Today's Price Move, Forecast, and Earnings pages.
Analyst Price Targets and Consensus View
Coverage of BFRI remains limited, which makes any consensus unusually fragile. Two current, attributable price targets form the basis of the $6.00 figure. Benchmark analyst Bruce Jackson lowered the rating to Speculative Buy from Buy on May 19, 2026 while maintaining a $3.00 target, citing the company's small market cap. Roth MKM analyst Jonathan Aschoff reaffirmed a Buy rating with a $9.00 target on May 15, 2026.
The arithmetic mean of $3.00 and $9.00 is $6.00, rounded. The wide $3.00-to-$9.00 range matters more than the headline number: it shows two firms with fundamentally different views of how much the sBCC label expansion should change the stock's value. Both ratings remain bullish in direction, but the spread is a reminder that a small sample of targets carries limited predictive weight. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
With shares near $0.89 and a 52-week range of roughly $0.56 to $1.66, BFRI sits closer to its lows than its highs. Reaching $6.00 would require an increase of about 575%, a move that would be extraordinary for any stock and is best understood as a multi-year transformation rather than a near-term re-rating. The company's market capitalization is only about $13 million, so even modest infusions of investor interest can move the share price sharply in either direction.
The path toward such a target would depend on converting the sBCC approval, which Biofrontera plans to launch commercially between late 2026 and early 2027, into durable revenue growth on top of its existing actinic keratosis franchise. Trailing-twelve-month revenue is about $46 million, while the company continues to report net losses, with EPS around -$0.43 over the same period.
What Could Support a Move Toward the Target
- In September 2026, the FDA approved Ameluz used with the BF-RhodoLED lamp series for superficial basal cell carcinoma, making it the first PDT drug approved in the U.S. to treat a skin cancer. Basal cell carcinoma is the most common U.S. skin cancer, with roughly 3.6 million cases annually, and the superficial subtype is estimated at 15% to 20% of those cases.
- Management reiterated a goal of breaking even on an operating cash flow basis in 2026, and the company reported record quarterly revenue around $17 million for the fourth quarter of 2025.
- A positive Phase 3 readout for Ameluz in actinic keratosis on the extremities, neck, and trunk, plus encouraging Phase 2b acne data, broaden the pipeline beyond the current label.
What Could Prevent the Target From Being Reached
- Persistent losses and limited cash constrain investment in the commercial launch and clinical development. Total cash was around $4.7 million in the most recent quarter, with negative levered free cash flow.
- The company received a Nasdaq notice on bid-price noncompliance in late 2025, a factor that can pressure shareholders through dilution or a reverse split.
- A micro-cap structure means financing risk is acute, and any capital raise could offset fundamental progress.
- Analyst disagreement is itself a risk signal: a $3.00 target sits far below the $6.00 average, reflecting the possibility that the sBCC opportunity underwhelms commercially.
Technical Levels and Market Structure
BFRI trades below the $1.00 psychological level and well under its 52-week high near $1.66. The 52-week low near $0.56 represents the key support level to monitor, while the $1.00 mark and the prior high near $1.66 serve as notable resistance levels. Because the $6.00 target lies more than three times above the stock's all-time trading range in the past year, conventional chart-based support and resistance offer limited guidance for that magnitude of move.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month horizon, though neither firm has publicly detailed a precise time frame for its BFRI objective. The next quarterly earnings report is scheduled for November 13, 2026, and investors should watch for sBCC launch commentary, progress toward cash-flow breakeven, and any update on the Nasdaq listing status. Additional catalysts include clinical readouts for the acne and actinic keratosis programs and any changes to analyst targets after the first full quarter of the expanded label.
Final Assessment
The $6.00 central target is an arithmetic average of just two analyst objectives, $3.00 and $9.00, rather than a broad Street consensus. It sits roughly 575% above the current price, meaning the move required is very large and would demand a multi-year re-rating. The sBCC approval is a genuine, verifiable positive that expands the addressable market and gives the company a differentiated position in medical dermatology. Against that, ongoing losses, a thin cash position, Nasdaq listing risk, and a micro-cap structure all weigh heavily. Whether BFRI reaches $6.00 will hinge less on the headline target and more on whether the commercial launch translates into sustained, cash-flow-positive growth. No price prediction is offered here, and investors should weigh the wide analyst range and the company's financing constraints carefully.
Exploring AI Daily Buy/Sell Signals
In my own research process, I often review Tickeron's AI Daily Buy/Sell Signals to add a systematic layer to fundamental analysis. The tool uses artificial intelligence to monitor thousands of stocks and generate Buy, Sell, or Hold signals based on technical behavior and market conditions. It helps me spot shifting trends more efficiently and cross-check short-term momentum alongside longer-term views like the one for BFRI.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BFRI's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for BFRI turned positive on October 26, 2026. Looking at past instances where BFRI's MACD turned positive, the stock continued to rise in 39 of 44 cases over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BFRI's RSI Indicator exited the oversold zone, 24 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on BFRI as a result. In 68 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
Following a +12.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where BFRI advanced for three days, in 190 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 43 cases where BFRI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BFRI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for BFRI entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.065) is normal, around the industry mean (6.379). P/E Ratio (-1.926) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.307) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. BFRI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BFRI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement